Stay updated on Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated to include new interventions and the addition of the drug Tucatinib, with the revision now at v2.10.0, replacing the previous version v2.9.7.
    Difference
    1%
    Check dated 2024-07-23T14:37:59.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.2%
    Check dated 2024-07-16T06:22:46.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-07-02T13:48:03.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-27T09:51:20.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-26T08:39:59.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value Revision: v2.9.0 has been updated to Revision: v2.9.1, indicating a new version of the content with additional information related to MedlinePlus Genetics topics, drug information for Tucatinib, expanded access options, and keywords provided by Seagen Inc.
    Difference
    13%
    Check dated 2024-06-25T08:21:10.000Z thumbnail image

Stay in the know with updates to Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.